Our findings demonstrate the therapeutic effects of over-the-counter drug Fexofenadine in treating IBD and provide first in vivo evidence showing that cPLA2 is required for Fexofenadine’s therapeutic effects in IBD and probably other inflammatory and autoimmune diseases as well. This evidence concerns the gene PLA2G4A and inflammatory bowel disease.